Browse > Article

The Adjuvant Effect of Subcutaneous Interferon-gamma in the Treatment of Refractory Multidrug-resistant Pulmonary Tuberculosis  

Kim, Eun Kyung (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Shim, Tae Sun (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Lee, Jung Yeon (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Oh, Yeon-Mok (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Lim, Chae-Man (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Lee, Sang Do (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Koh, Younsuck (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Dong Soon (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Won Dong (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Woo Sung (Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.3, 2004 , pp. 226-233 More about this Journal
Abstract
Background : Interferon-gamma (IFN-${\gamma}$) is a critical cytokine in the defense against a Mycobacterium tuberculosis infection. Even though IFN-${\gamma}$ has occasionally been used in the treatment of refractory multidrug-resistant tuberculosis (MDR-TB) with some promising results, there is still some controversy regarding the therapeutic efficacy of IFN-${\gamma}$. This study was performed to examine the effect of subcutaneous IFN-${\gamma}$ in the treatment of MDR-TB patients. Methods : Six patients with refractory MDR-TB were enrolled in this study. Two million IU of IFN-${\gamma}$ was administered subcutaneously three times a week with the concomitant administration of antituberculous drugs for at least for 28 weeks. During the IFN-${\gamma}$ therapy, the sputum smear and culture, radiological and clinical evaluations were performed every 4 weeks throughout the study period. Results : The mean age of the 6 patients was 37 years (ranges, 15-61 years). The drug susceptibility test to standard antituberculous drugs revealed resistance to an average of 6.8 (${\pm}1.2$) agents including isoniazid and rifampicin. An average of 10.8 (${\pm}1.3$) antituberculous drugs were prescribed before IFN-${\gamma}$ therapy. The culture became negative in 2 patients (33%) after initiating IFN-${\gamma}$ therapy; one at 8 weeks, and the other at 24 weeks. Finally, after stopping the IFN-${\gamma}$ therapy after 28 weeks, the culture became positive again in the two patients who were culture-negative. The other 4 patients who failed in the culture conversion are still on antituberculous treatment except for one who died of tuberculosis. Conclusion : Even though 28 weeks of subcutaneous IFN-${\gamma}$ therapy in combination with antituberculous drugs was successful in inducing the culture-negative conversion in some patients with refractory MDR-TB, the culture became positive again after stopping the IFN-${\gamma}$ therapy. This suggests that subcutaneous IFN-${\gamma}$ therapy may have suppressive effect on tuberculosis only during the IFN-${\gamma}$ therapy period in some patients. Further studies will be needed to determine the optimum dose, the administration route, the duration of therapy, and the predicting factors of the response to adjuvant IFN-${\gamma}$ therapy.
Keywords
Drug Resistance; Multiple; Interferon-gamma; Tuberculosis; Pulmonary;
Citations & Related Records

Times Cited By SCOPUS : 3
연도 인용수 순위
1 Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6
2 Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, Sherwin SA, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986;315:6-15
3 Antoniou KM, Ferdoutsis E, Bouros D. Interferons and their application in the diseases of the lung. Chest 2003;123:209-16
4 Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993;178:2243-7
5 Holland SM, Eisenstein EM, Kuhns DB, Turner ML, Fleisher TA, Strober W, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994;330:1348-55
6 Squires KE, Brown ST, Armstrong D, Murphy WF, Murray HW. Interferon-gamma treatment for Mycobacterium avium-intracellulare complex bacillemia in patients with AIDS. J Infect Dis 1992;166:686-7
7 Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993;178:2249-54
8 Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37
9 Johnson BJ, Ress SR, Willcox P, Pati BP, Lorgat F, Stead P, et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 andmultidrug therapy. Cytokines Mol Ther 1995;1:185-96
10 Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, Lee NY, et al. Six-month therapy with aerosolized interferon-$\gamma$ for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004;19:167-71
11 Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-9
12 Raad I, Hachem R, Leeds N, Sawaya R, Salem Z, Atweh S. Use of adjunctive treatment with interferon-gamma in an immunocompromised patient whohad refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis 1996;22:572-4
13 Bloom BR, Murray CJ. Tuberculosis: commentary on a reemergent killer. Science 1992;257:1055-64
14 Palmero D, Eiguchi K, Rendo P, Castro Zorrilla L, Abbate E, Gonzalez Montaner LJ. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis 1999;3:214-8
15 Squires KE, Murphy WF, Madoff LC, Murray HW. Interferon-gamma and Mycobacterium avium-intracellulare infection. J Infect Dis 1989;159:599-600
16 Kaplan G, Mathur NK, Job CK, Nath I, Cohn ZA. Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad SciUSA 1989;86:8073-7
17 Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996;335:1956-61
18 Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997;349:1513-5
19 Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991;72:1-6
20 Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995;123:216-24
21 Holland SM. Cytokine therapy of mycobacterial infections. Adv Intern Med 2000;45:431-52
22 Lopez􀁔Maderuelo D, Arnalich F, Serantes R, Gonzalez A, Codoceo R, Madero R, et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003;167:970-5
23 Kemper CA, Bermudez LE, Deresinski SC. Immuno-modulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use ofrecombinant granulocyte-macrophage colony-stimulating factor. J Infect Dis 1998;177:914-20
24 Kaplan G, Britton WJ, Hancock GE, Theuvenet WJ, Smith KA, Job CK, et al. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med 1991;173:993-1006
25 Giosue S, Casarini M, Alemanno L, Galluccio G, Mattia P, Pedicelli G, et al. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998;158:1156-62